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Introduction
    Parkinson’s disease (PD) is a progressive neurodegenerative 
disorder, affecting around 1% of the population over the age of 60. 
With this ratio it is the second most common neurodegenerative 
disease after Alzheimer’s disease [1]. As the population is getting 
older, the number of PD patients is continuously increasing. PD is 
characterized by the loss of dopaminergic (DAergic) neurons of the 
substantia nigra pars compacta (SNpc), and the presence of Lewy 
bodies (intracytoplasmic α-synuclein inclusions) in the surviving 
neurons [2, 3]. The decreased dopamine (DA) level in the striatum 
leads to disrupted connections to the thalamus and motor cortex [4]. 
thus resulting in mainly motor symptoms. The most typical signs 
include tremor, rigidity and bradykinesia [5]. Although the exact 
cause of the disease is still unidentified, it is proven that several genes 
have a role in PD, such as the genes coding α- synuclein, Parkinson 
disease protein 7 (PARK7), parkin and phosphatase and tensin 
homologue-induced kinase 1 (PINK1) [6]. We must also take enviro-
nmental factors into consideration, as enough evidence exists that 
age, gender, tobacco, caffeine consumption and pesticide exposure 
are associated with the development of the disease [7]. The therapy 
which would avoid the progression of the dopaminergic cell 
degeneration is still unknown, current therapeutical options of PD 
mainly focus on the substitution of DA, however, several side- effects 
have been described [8, 9]. As pharmacological therapy has its 
limitations numerous studies focusing on non-pharmacological 
methods have been emerging during the last few decades. It has been 
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Abstract 
Parkinson’s disease is the second most common neurodegenerative disease after Alzheimer’s disease. Although its exact cause is still 
unidentified, it is proven that several genes and also environmental factors have a role in its development. As pharmacological therapy 
has its limitations numerous studies focusing on non-pharmacological methods have been emerging during the last few decades. It has 
been described that several environmental factors can change the prevalence and outcome of Parkinson’s disease. The positive 
environmental factors, stimulus-rich environment and exercise can be modeled by environmental enrichment. The aim of the current 
review is to summarize data on the role of environmental enrichment in different models of Parkinson’s disease. Based on the results it 
is assumable that enriched environment is able to alter both behavioral and cellular changes appearing in models of PD, hence it could 
provide a non-pharmaceutical, non- invasive method for possible prevention and treatment of Parkinson’s disease without the side-
effects of pharmacotherapy.
Keywords: Enriched Environment; Parkinson’s Disease; MPTP; 6-OHD.
Positive environmental factors, stimulus-rich environment and exe-
rcise can be modeled in laboratory by environmental enrichment (EE). 
The beneficial effects of EE were first proposed by Donald Hebb, when 
he described that rats raised at home with his children along with 
other toys presented improved cognitive performance compared to 
their mates in the laboratory [14]. Since then thousands of studies 
have reinforced the positive effects of EE. It has an impact on both 
developing and intact or damaged mature brain [15, 16]. EE stimulates 
synapse formation, increases angiogenesis [17]. gliogenesis in cortical 
regions [18] and has an effect on cortical thickness [19]. Our research 
group has also described its protective effects in case of postnatal 
asphyxia [20] monosodium-glutamate-induced toxicity [21] as well as 
neonatal and adult retinal lesions [22, 23]. Importantly, EE is proven 
to be neuroprotective in numerous models of psychiatric and 
neurodegenerative diseases, such as drug addiction, depression, 
Huntington’s, Alzheimer’s and Parkinson’s disease [16, 24, 25].
       The aim of the current review is to summarize data of studies on 




        In this review we summarize results obtained from mouse and rat 
models of PD. The details and results of each study are summarized in 
Table 1. Mice were treated with MPTP injections, while rats received 
6-OHDA treatment to induce PD. One of the most common models
of PD is the administration of MPTP [26-28]. MPTP is converted to
the toxic MPP+ by monoamine oxidase-B (MAO-B) of glial cells,
which is taken up into neurons by the dopamine transporter (DAT);
MPP+ inhibits NAD(H)-linked mitochondrial oxidation at the level of
Complex I of the electron transport system [29] leading to the loss of
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Duration of EE Cellular and biochemical effects Behavioral effects Author, date 
Rats treated with 6-0HDA 
3 months postnatal 5 weeks decreased DAergic cell loss recovery in free rearing activity 
higher distance covered
Juigling, 2017 




less TH-positive neuronal loss 
pre served nigrostriatal pathway 
prevented early neuronal degenerati 
on increased GFAP-p 
reduced rotational behavior Anastasia 2009 
8 weeks before 6-0HDA ital. 5 weeks enhanced neuronal migration towards striatum better performance an beam ‘,•alking Urakawa, 2007 
adult after 6-OHDA inj. 4 or 7 weeks increased cell proliferation in s.n.
increased number o f necrvb am NG2-positive cells 
increased number af newb om GFAP-positive cells 
no effect on the number of 
reduced rotational behavior (7 weeks) Steiner, 2006 
adult before 6-OHDA inj. higher number o f residual TH-positive cells improved skilled movement accuracy 
no rotational asymetry
Jadavji, 2006 
adult before 6-OHDA inj. 13 weeks increased survival of grafted striatal DAergic neurons reduction of drug-induced rotation




Mice treated with INIPTP 
8-9 weeks before MPTP inj.
after MPTP inj.
40 days  
20 days 
restored DOPAC and HVA levels in 
striatum increased DA turnover in striatum 
increased D1R expression in the midbrain
inhibited NIPTP-induced hyperlocatnation 
similar muscle strength to saline-treated mice
Hilario, 2016 





one week after first MPTP 
inj. 
3 weeks 
restoration of TH-positive neurons increased number of total years (in young) 
recovered free-standing rear 
behaviour improved motor control 
(in aged)
Goldberg. 2011 
6 months 3 months 3 months less decreased expression of TH 
lower loss of TH-pasitive neurons 





5-7 months 2-3 months no TH-positive cell death  
reduced DAT expression 
decreased VMAT2 expression 
increased GDNFexpression
Faherrv, 2005 
3 months before 21PTP inj. higher number of surviving TH-positive cells 
decreased DAT expression in striatum 
increased BDNFf expression 
Bezard 2003 
months 





SNpc cells, thus recapitulating the pathology of PD [30, 31]. In cells 
MPP+ can be sequestered into intracellular vesicles by the vesicular 
monoamine transporter 2 (VMAT2), which can offer some degree of 
protection against MPTP [32, 33]. 6-OHDA injections result in oxida-
tive stress-induced apoptosis of the DAergic cells, as the toxin itself is 
highly unstable and after being taken up by the cells it degrades 
causing formation of superoxide, hydrogen peroxide and hydroxyl 
radicals [34]. One experiment used both 6-OHDA and quinolinic acid 
injections into the striatum [35].
 Most studies were performed in young or adult animals, between 
8-week- to 7-month- old individuals. Only one experiment investiga-
ted the effects of enriched housing conditions in aging, in 12-month-
old mice [36] suggesting that this experimental setup gives a better
model of the human disease. It is known that PD has increased
prevalence in the older population, and its symptoms appear mostly
after the age of 60 [37, 38]. It is also established that animals of older
ages are more vulnerable to MPTP and 6-OHDA insult [10, 39]
therefore it is crucial to explore possible treatment options in models
of PD in aged animals. Yuan and coworkers performed their
examinations on SAMP8 mice, which are senescence- accelerated-
prone animals, serving as useful models for age-dependent diseases,
such as PD [40, 41].
Environmental enrichment
      The term ‘environmental enrichment’ refers to altered housing 
conditions, where the animals are placed into larger cages, compared 
to standard cages (SE: standard environment). Regular cages typically 
only consist of nesting material, while enriched cages are suppleme-
nted with different toys, running wheels, platforms, tunnels, rotating 
rods of different shape, size and material [Figure 1]. There is no 
standard protocol to create an enriched cage, but the main aim is to 
provide complex sensorimotor and cognitive stimuli, which is ensu-
red by the continuous change of the supplies [16]. In the reviewed 
studies the frequency of changing the toys varied between daily to 
weekly changes. Several experiments included a social enrichment 
factor, as higher number of animals was kept in the enriched cages 
[36, 42, 43].
       Overall, the time spent in enriched housing conditions changed 
between 3 weeks to 3 months. Mice were exposed to EE following 
MPTP injections for either 3 weeks [9, 36] or 70 days [44] or prior to 
MPTP injections for 40 days [9], 2 months [45] or 3 months [42, 43].
       Rats were reared in enriched cages for 3 [46], 5 [35, 47], 6 [48] or 
13 weeks [49] before and 3 [46], 4 or 7 weeks [50] after inducing PD 
by 6-OHDA. The age when the animals were put into enriched cages
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was also different in each study [Table 1].  
Figure 1: Representative picture of an enriched cage in our laboratory (47). 
Summary of results
Behavioral signs
      Behavioral signs and the possible improvement of motor symp-
toms were assessed in the majority of studies. The capacity of EE to 
reverse motor deficits was proven by several types of tests in mice. 
After MPTP-injections and subsequent 3 weeks of EE young mice 
showed increased number of total rears. The decreased ratio of foot 
faults to total activity in the parallel rod activity chamber test indi-
cated improved motor control in aged mice, while a recovery of free-
standing rears was visible both in young and aged groups [36].
        In mice, placed in EE prior to MPTP lesion, numerous tests have 
proven the beneficial effects of EE. Evaluating the mean number of 
movements, enriched animals showed less decreased spontaneous 
activity [42]. Hilario et al observed hyperlocomotion in MPTP-
treated animals, which was prevented by EE, based on the total 
distance traveled in open field test. Grip test demonstrated increased 
muscle strength after enrichment alone, while MPTP-treated 
enriched animals had similar performances to saline-treated groups 
[9]. Apart from motor symptoms PD patients may have emotional 
and cognitive problems which were also assessed by elevated plus 
maze instrument; the test showed reduced anxiety levels in enriched 
mice [42].
  Most experiments conducted on rats involved behavioral 
examinations. Rats raised in EE for 6 weeks before unilateral 6-
OHDA treatment (into the nigrostriatal bundle) had significantly 
higher reaching success in skilled reaching task. Furthermore EE 
animals had better error scores in skilled walking tests and made less 
severe placement errors compared to control animals [48]. The 
evaluation of apomorphine-induced rotations revealed an absent 
rotational asymmetry in enriched rats, as SE animals rotated 
significantly more towards the side contralateral to the lesion [48]. 
Our research group has also tested the effects of prophylactic 
enrichment; furthermore we were the first to provide evidence for the
protective effect of early, postnatal enrichment, when rats were kept 
in enriched cages for 5 weeks directly after birth and received 6-
OHDA injections only several months later in adulthood [47]. In 
open field test we explored a reduced free rearing activity in both 
standard and enriched rats, however, enriched animals showed a 
better ability for compensation, as some degree of recovery was 
visible on the tenth postoperative day. When evaluating the distance 
covered by the animals enriched rats had better performance, they 
did not move significantly less in the postoperative period, similarly 
to their standard mates. In this study we did not observe asymme-
trical behavioral signs [47]. Urakawa and co-workers assessed motor 
symptoms with beam walking test and observed better performance 
in enriched animals. In cylinder test they did not find differences in 
asymmetrical forelimb use between enriched and control animals 
[35]. In rats receiving intrastriatal dopaminergic grafts prior to the 
lesion the graft itself could not inhibit functional impairments caused 
by 6-OHDA [49] in contrast, grafted enriched animals showed 
reduced drug-induced rotational behavior and increased activity and 
better performance in spatial alternation test.
      Rats kept in EE after 6-OHDA injections also displayed incre-
ased physical activity on a rotarod [50]. In this experimental setup 
animals showed a trend towards improved drug- induced rotational 
behavior compared to control rats after 7 weeks of enrichment, and 
they exerted significantly reduced rotational behavior when compa-
red to animals reared in EE for only 4 weeks [50]. In order to explore 
functional impact of EE before and after 6-OHDA- induced lesion 
amphetamine-induced rotational behavior was measured, which 
showed reduced number of rotations in enriched rats [46].
Cellular and biochemical effects
     A frequent strategy to evaluate the severity of the lesion is to 
examine the nigral dopaminergic cell loss and the striatal changes.
     In case of enrichment prior to the lesion the number of TH-
immunoreactive (-ir) neurons [42, 45] and TH mRNA expression were
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higher [42] compared to mice kept in standard cages. Three months of 
preconditioning in EE completely protected the DAergic cells of the 
SNpc [43]. The expression of monoamine transporters were assessed 
in numerous studies, while searching for an explanation for the 
reduced toxicity. In enriched mice, a reduced number of DAT-ir cells 
[42] and lower expression of DAT mRNA was described in the SN
[42, 43]. Bezard and co-workers described significantly decreased
DAT binding and DAT mRNA levels in the striatum of mice raised in
EE compared to SE animals [45]. Following MPTP exposure the
decrease of VMAT2 can also contribute to the protective effect of EE.
It caused a significant decrease in VMAT2 mRNA expression of the
SN in adult mice compared to standard animals [43]. The expression
of different growth factors is often examined in PD models. Mice
accommodated in EE in adulthood had higher GDNF mRNA
expression in the SN, and even more raise could be detected after
receiving MPTP [43]. The raise in BDNF levels in the striatum of EE
mice may suggest that the protection of environmental effects could
be mediated by the increase of expression of growth factors [45].
induced lesion a restoration in the number of TH-expressing neurons 
was visible, which was confirmed by retrograde Fluorogold labeling 
indicating preserved nigrostriatal pathway [46]. In enriched animals 
reduced cell degeneration in the anterior SNpc, and induced nigral 
astrocytic reaction (higher numbers of GFAP-labeled cells) were 
found early after the toxin exposure [46].
Discussion
       By virtue of these above summarized studies, it is assumable that 
enriched environment is able to alter both neurochemical and 
behavioral changes in models of PD. There are various studies which 
describe effects of EE explaining its potential protective role in 
neurodegenerative diseases [24, 25]. Mice reared in EE from weaning 
to adulthood show alterations in the expression of striatal genes 
involved in cell proliferation, differentiation, intercellular signaling 
and cell metabolism. Among others an increased level of protein 
kinase C lambda, which is suggested to play an important role in 
neuroprotection and the plasticity of nervous system [51, 52]. In 
models of Huntington’s disease EE has been shown to delay motor 
symptoms and cognitive deficits. In Alzheimer’s disease an enhanced 
memory and learning and in case of epilepsy increased resistance to 
seizures have been described after EE. In stroke models enrichment 
resulted in an improved functional recovery of motor and cognitive 
deficits [24, 25].
 The studies summarized in this review all point towards the 
protective effects of enriched circumstances in PD. Exercise and 
increased physical activity are important components of enrichment. 
It has been shown that exercise alone could convey neuroprotective 
effects of MPTP-induced lesion, however, it was at a reduced degree 
compared to EE mice. This protection was supported by evaluating 
the death of TH- positive neurons. Also, an increased level of GDNF 
in SN and BDNF in striatum; and decreased DAT and VMAT2 
transporter mRNA expressions were found in mice performing 
exercise [43]. Similarly to these growth factors, our research group 
described that 3-week-long exposure to EE also induces elevation in 
PACAP levels in most areas of the CNS. The peptide PACAP has 
strong neuroprotective effects, its increase could play a role in the 
beneficial effects of EE [53].
    The fact that research groups found significant differences in the 
behavior of enriched animals compared to standard controls indicates 
that enriched environment potentially provides functional ameliora-
tion and improvement of motor symptoms. The improvement was 
described in skilled and non-skilled motor tasks, exploration of rotati-
onal movements, which are suitable to assess the severity of symptoms 
after unilateral lesions [48]. 
     The fact, that some investigations found asymmetrical signs, while 
others did not might be due to the difference in the extent of injury. 
As we know more than the half of dopaminergic neurons should be 
lost to lead to asymmetrical behavior [10, 54]. The functional outcome 
of enrichment was different when animals spent different amount of 
time in enlarged cages, only long-term stimulation could induce 
improvement in rotational behavior [46, 50]. Dobrossy et al. also 
described that EE on its own could not prevent drug-induced ipsila-
teral rotation, however it could enhance the functional improvement 
of animals additionally receiving intrastriatal dopaminergic grafts 
[49]. Open field tests were used in both mouse and rat models and 
revealed better performances during the examination of free rearing 
activity, distance covered and spontaneous activity. Although 
hypokinesia is one of the main characteristics of PD one study 
described hyperlocomotion after  MPTP injections, which had been 
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 Both young and aged mice showed a significant recovery in the 
mean number of TH- positive neurons in the SNpc when kept in EE 
for 3 weeks after MPTP-lesioning [36]. Klaissle and coworkers descri-
bed that enrichment could increase the number of newly formed 
neural precursors in SN if co-treated with levodopa. Also, the incre-
ased formation of NG2+ (neuro-glial antigen-2) cells in enriched 
animals depended on levodopa treatment [44]. These cells are 
capable to differentiate into oligodendrocytes, and even to neurons in 
vitro, which offer a possible regenerative capacity in the midbrain [44].
 Exposure to EE both before and after MPTP injection led to 
restoration of 3,4- dihydroxyphenylacetic acid (DOPAC) and 
homovanillic acid (HVA) levels in the striatum, but it was not able to 
prevent DA depletion. Animals, which received MPTP and were 
housed in EE had an increased DA turnover [9]. Hilario et al. also 
evaluated changes in the expression of DAergic-related genes in the 
midbrain (SN+VTA), among which only the expression of 
dopaminergic receptor D1 (D1R) was reduced after EE. The gene 
expression of the cholinergic system was also examined in this study 
[9].
 In rats living in enriched cages prior to the lesion, examinations 
revealed higher number of residual TH-positive cells in the medial 
and ventral tegmental area, SNpc and lateral part of SN. In contrast, 
cortical thickness and brain weight measurements did not find 
significant differences between SE and EE rats [48]. In case of 
postnatal enrichment, in concordance with previous data we found 
that enriched circumstances could rescue the dopaminergic cells [47]. 
When animals were reared in EE for 5 weeks prior to lesion no 
significant differences were found between control and enriched 
animals regarding DAergic cell loss, however an increased number of 
migrating doublecortin-positive (DCX-positive) cells were found in 
the lesioned striatum of enriched animals [35]. These cells were 
suggested to be detached from neuroblasts in the subventricular zone 
(SVZ). Moreover, it has been proven that enriched circumstances can 
improve the survival of DAergic grafted cells in the striatum [49].
 Exposure to enriched environment after 6-OHDA injection did 
not change the number of TH-positive cells compared to lesioned 
controls. However enrichment led to increased cell proliferation, 
additionally the number of newborn NG2- and GFAP-positive cells 
was significantly higher in enriched lesioned rats [50] similarly to the 
results of Klaissle et al. [44].
        When enrichment was applied both before and after 6-OHDA-
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reported earlier by several research groups [55, 56]. This symptom can 
be explained by pre-synaptic dopamine 1 receptor hypersensibili-
zation due to the severe loss of nigral DA [57, 58]. EE- applied both 
before and after MPTP injections- prevented hyperlocomotion while 
decreasing the expression of D1R [9]. In this experiment EE did not 
have an effect on DA levels; it only restored grip strength, which was 
described in similar models [59, 60]. These observations were 
confirmed by several rat studies, when no significant difference was 
found it the percentage of surviving neurons of the SN, but enriched 
animals still exerted less severe motor symptoms [47, 50]. The better 
performance of enriched animals on beam walking test further proves 
that environmental enrichment can improve balance, coordination 
skills and sensory ability [35]. These results showing that enriched 
environment can alter functional outcome after different types of 
lesions correspond to earlier findings of several research groups [61, 
62].
   Numerous research groups provided evidence that enriched 
animals are more resistant to MPTP or 6-OHDA, as the number of 
surviving TH-positive neurons were higher in SNpc compared to 
standard animals. Neural transplantation of DAergic cells could also 
offer a solution to PD. Currently the two main approaches to enhance 
the survival of grafts are to change the microenvironment of the grafts 
and to alter environmental factors around the time of the lesion [63]. 
In 2000, Dobrossy and coworkers proved that EE prior to lesion can 
increase the survival of grafted DA producing cells in the rat striatum 
[49] thus the success of grafting could be further optimized by
increasing the complexity of environment.
 Although the mechanisms underlying the protective effect of EE 
are not yet completely understood, studies discuss several changes 
which may support the recovery of enriched animals. It has been 
excluded that the protective effect of EE would be due to the change in 
MPTP metabolism, as the conversion of the toxin to MPP+ was not 
different in enriched compared to standard animals [43]. The 
reduction of DAT gene expression and the depletion of the number of 
DAT-ir cells is a possible mechanism of protection against MPTP- 
induced toxicity; hence DAT plays a crucial role in the uptake of the 
neurotoxin. It is proven that mice lacking DAT are protected from 
MPTP-induced neuronal death [64]. Exercise alone can cause a 
significant loss of DAT protein in the striatum of MPTP-treated mice 
[65]. The change in VMAT2 expression observed could also 
contribute to the neuroprotective effect of EE. VMAT2-mediated 
sequestration of the neurotoxin may take part in alleviating MPTP 
toxicity. It has been demonstrated that mice lacking VMAT2 are more 
susceptible to the neurotoxic effects of MPTP [32]. Furthermore, 
treatment with VMAT2 inhibitor enhances MPTP toxicity in the 
striatum of rats [33].
 Several findings support that enriched conditions stimulate cellular 
plasticity, rather than having direct neuroprotective effects. It is 
known that SN does not have the regenerative capacity to form new 
dopaminergic neurons. However it has been shown that non-neuronal 
NG2-expressing cells, with mainly oligodendrocytic precursor 
characteristics could be generated [50, 66]. The aim of future therapy 
of PD would be to restore the nigral dopaminergic neurons, and as 
NG2+ cells can potentially differentiate into neurons, they may offer a 
new therapeutic option [67, 68]. The fact that EE enhances the 
generation of these cells in a levodopa-dependent way [44] further 
shows that EE exerts its protective effects through numerous 
mechanisms. 6-OHDA causes a decrease in GFAP-positive glial cells, 
however in the study of Steiner et al. the newborn cells induced by 
physiological stimuli also expressed GFAP, thus glial plasticity might 
be a way of compensatory processes [50]. However a large number of 
 newborn cells did not express any markers of neurons, astrocytes, 
oligodendrocytes or microglia; they are suggested to undergo deve-
lopment or maturation. Anastasia and coworkers also suggests that an 
early post-lesional astrocytic reaction may take part in the prote-ction 
of the entire nigrostriatal system [46]. Urukawa et al. described an 
increased number of migrating DXC-positive neurons in the striatum 
of enriched animals which were co-expressed with CXC chemokine 
receptor 4 (CXCR4). This, together with the found up-regulation of 
stromal cell-derived factor 1α (SDF-1α) mRNA, sugge-sts that SDF- 
1α/CXCR4 signaling might regulate the activation of DXC-positive 
cells after environmental stimuli [35]. Altogether these studies 
mentioned above suggest that complex stimuli are not able to enhance 
the formation of new DAergic neurons, but induce some 
microenvironmental changes in the SN, which lead to functional 
improvements.
Conclusions
 The neuroprotective effects of EE have been well established by 
numerous studies, which raise the question whether we should pay 
more attention and focus should be placed also on providing a 
stimulating environment during clinical therapy and rehabilitation of 
patients suffering from PD. EE could provide a non-pharmaceutical, 
non-invasive method for possible prevention and treatment of 
Parkinson’s disease without the side-effects of pharmacotherapy.
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